Journal
CELLS
Volume 10, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/cells10030659
Keywords
signaling pathways; targeted therapies; combinatorial treatments; oncogenes and tumor suppressors; cancer resistance; RTK; PROTACS
Categories
Funding
- NHMRC New Investigator Grant [APP1100307]
- Victorian Cancer Agency (VCA) Mid-career Research Fellowship
Ask authors/readers for more resources
Molecular alterations in cancer genes and signaling pathways play a crucial role in guiding precision medicine treatments for cancer, but inherent limitations such as drug toxicity and resistance mechanisms still pose challenges. Combination therapies may become the preferred approach for cancer treatment in the future, and novel therapeutic developments hold promise for significantly improving clinical response and outcomes for cancer patients.
Molecular alterations in cancer genes and associated signaling pathways are used to inform new treatments for precision medicine in cancer. Small molecule inhibitors and monoclonal antibodies directed at relevant cancer-related proteins have been instrumental in delivering successful treatments of some blood malignancies (e.g., imatinib with chronic myelogenous leukemia (CML)) and solid tumors (e.g., tamoxifen with ER positive breast cancer and trastuzumab for HER2-positive breast cancer). However, inherent limitations such as drug toxicity, as well as acquisition of de novo or acquired mechanisms of resistance, still cause treatment failure. Here we provide an up-to-date review of the successes and limitations of current targeted therapies for cancer treatment and highlight how recent technological advances have provided a new level of understanding of the molecular complexity underpinning resistance to cancer therapies. We also raise three basic questions concerning cancer drug discovery based on molecular markers and alterations of selected signaling pathways, and further discuss how combination therapies may become the preferable approach over monotherapy for cancer treatments. Finally, we consider novel therapeutic developments that may complement drug delivery and significantly improve clinical response and outcomes of cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available